Generics industry, FDA agree on $299M for US user fee programme
This article was originally published in SRA
Executive Summary
Generic drug makers have agreed to pay $299 million in annual user fees to the US Food and Drug Administration, according to recently disclosed summaries from meetings at which industry and regulators have been working on a deal to create the country's first user fee programme for generics1-3.